Teva agrees to buy Allergan's generic-drug unit for US$40.5b
Deal allows Israeli drugmaker to extricate itself from its increasingly antagonistic pursuit of Mylan
London
ISRAELI drugmaker Teva Pharmaceuticals Industries Ltd has agreed to buy the generic-drug business of Allergan plc for about US$40.5 billion in cash and stock, and ended its hostile bid for Mylan NV.
Teva will pay US$33.75 billion in cash and US$6.75 billion worth of shares at Monday's price, or about 10 per cent of the enlarged company, the Petach Tikva, Israel-based company said in a statement. Teva surged as much as 11 per cent as trading resumed in Tel Aviv.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices